UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 31, 2011
|
Bacterin International Holdings, Inc.
|
|
(Exact Name of Registrant as Specified in Its Charter)
|
|
Delaware
|
|
|
(State or Other Jurisdiction of Incorporation)
|
|
001-34951
|
20-5313323
|
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
600 Cruiser Lane
Belgrade, Montana
|
59714
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
(406) 388-0480
|
||
|
(Registrant’s Telephone Number, Including Area Code)
|
|
(Former Name or Former Address, if Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
The Company has issued a press release entitled “Bacterin to Present at Lazard Capital Markets 8th Annual Healthcare Conference on November 16, 2011” which is attached as Exhibit 99.1 and incorporated herein.
The information in this Item 7.01 and the document attached as Exhibit 99.1 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No
|
Description
|
|
|
|
||
|
99.1
|
Press Release of Bacterin International Holdings, Inc. dated October 31, 2011 entitled “Bacterin to Present at Lazard Capital Markets 8th Annual Healthcare Conference on November 16, 2011”
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: October 31, 2011
|
BACTERIN INTERNATIONAL HOLDINGS, INC.
|
||
|
By:
|
/s/ Guy S. Cook
|
||
|
Name: Guy S. Cook
|
|||
|
Title: President and Chief Executive Officer
|
|||
EXHIBIT INDEX
|
99.1
|
Press Release of Bacterin International Holdings, Inc. dated October 31, 2011 entitled “Bacterin to Present at Lazard Capital Markets 8th Annual Healthcare Conference on November 16, 2011”
|
|||
Bacterin to Present at Lazard Capital Markets 8th Annual Healthcare
Conference on November 16, 2011
BELGRADE, MT, – October 31, 2011 – Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, has been invited to present at the Lazard Capital Markets 8th Annual Healthcare Conference. The conference will be held at The Pierre Hotel in New York City on November 15-16, 2011.
Bacterin’s chairman and CEO, Guy Cook, and CFO, John Gandolfo, are scheduled to present on Wednesday, November 16, 2011 at 11:30 a.m. Eastern time, with one-on-one meetings held throughout the day. Management will discuss the company’s business plan and objectives for the remainder of 2011.
The presentation will be available via webcast at www.wsw.com/webcast/lz11/bihi.ob/. A replay link will also be available for 90 days following the live presentation on the company’s website at www.bacterin.com.
Bacterin reported record revenue for the second quarter 2011 of $7.5 million, up 25% sequentially and 135% year-over-year. The company also reported its first positive EBITDA quarter of $33,000.
For more information about the conference or to schedule a one-on-one meeting with Bacterin management, contact your Lazard Capital Markets representative.
About Lazard Capital Markets
Lazard Capital Markets LLC provides corporate finance advisory services. It offers mergers and acquisitions, restructuring, and capital raising advisory services. The firm provides equity and fixed income sales and trading services. Additionally, it offers corporate underwriting services. The company was founded in 2005 and is based in New York, New York. For more information, please visit www.lazardcap.com.
About Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE Amex: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.
1
Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please visit www.bacterin.com.
Company Contact:
Guy Cook
President & CEO
Bacterin International Holdings, Inc.
Tel 406-388-0480
gcook@bacterin.com
Investor Relations:
Liolios Group, Inc.
Scott Liolios or Ron Both
Tel 949-574-3860
info@liolios.com
2